Transaction Terms
Pursuant to the terms and conditions of the Agreement, in consideration for 50% of the issued and outstanding Longevity Shares, the Company will issue an aggregate of 20,000,002 common shares in the capital of the Company (the “Payment Shares”) pro rata to the Shareholders at a deemed price of
The Payment Shares will not be subject to any hold periods under applicable securities laws. Any Shares issued in connection with the Milestone Payments will be subject to a four month hold period under
The Company is at arm’s length from Longevity and each of the Shareholders. Upon completion of the Transaction, Longevity's board of directors will be comprised of nominees of New Wave. No change in management or the board of directors of the Company is being contemplated at this time.
The Transaction is not expected to constitute a Fundamental Change for the Company (as defined in the policies of the Canadian Securities Exchange), nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”).
The Transaction remains subject to a number of conditions, including: the receipt of any required regulatory approvals including the approval of the CSE and the receipt of a third party valuation of Longevity. The Transaction cannot be completed until these conditions have been satisfied. There can be no guarantees that the Transaction will be completed as contemplated or at all.
ABOUT LONGEVITY AI INC.
Longevity, a private corporation existing under the laws of the state of
Longevity owns and operates proprietary technology that connects patients to cutting edge clinical treatments around bio markers, longevity, anti-aging protocols and the central nervous system. Further, Longevity has plans to use artificial intelligence to connect individual patient data with their desired health outcomes and create customized protocols in collaboration with clinical partners and care providers.
ABOUT
Investors interested in connecting with
For further information please contact:
ON BEHALF OF THE BOARD of DIRECTORS
Director
The CSE does not accept responsibility for the adequacy or accuracy of this release.
TheCanadianSecuritiesExchangehasnotinanywaypasseduponthemeritsoftheProposedTransactionandhasneitherapprovednordisapprovedthecontentsof thispress release.
The securities to be issued in connection with the Proposed Transaction have not been and will not be registered under the
This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When or if used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the potential acquisition of Longevity, including, the closing of the Transaction, if it is to close at all, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.
Source:
2023 GlobeNewswire, Inc., source